City Therapeutics prices IPO at $18 per share, raising $200M

City Therapeutics, a clinical-stage biotech focused on RNA interference, priced its IPO at $18 per share, aiming to raise around $200 million, according to a release. The offering, consisting of 11.11 million shares, could potentially see underwriters purchase an extra 1.67 million shares within 30 days at the same price. All shares are being sold directly by the company.

City Therapeutics' stocks are slated to debut on the Nasdaq Global Market on October 16, 2026, with the IPO set to close on October 19, 2026, pending usual closing conditions. Goldman Sachs, Jefferies, Stifel, and Oppenheimer are jointly managing the offering. The SEC officially approved the registration statement on October 15, 2026.

City Therapeutics' key programs include CITY-FXI for thromboembolic diseases, CITY-RBP4 for retinal conditions like Stargardt, and CITY-TFR2 targeting anemia in chronic diseases.